RFA-CA-21-026: Program on the Origins of Gastroesophageal Cancers (R01 Clinical Trial Optional)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2021.
National Institutes of Health offered grants to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on October 8, 2021.
From the official notice on Grants.gov, last changed June 25, 2021. Checked November 7, 2026.
- Award amountsNot given on Grants.gov
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- Activity codeR01
- Clinical trialsOptional
- Funded byNCI
- Median yearly award$912,376
- Typical project length5 years
- R01, Research Project Grant. NIH's standard grant for a defined research project led by a named investigator, usually for up to five years. Other open R01 notices.
Projects funded under RFA-CA-21-026 were run by National Cancer Institute (NCI, 6 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-CA-21-026 in the NIH Guide.
Key dates
| Posted | June 25, 2021 |
|---|---|
| Deadline | October 8, 2021 |
| Archived by Grants.gov | November 13, 2021 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Is this a realistic fit?
- Most of the program's money (69% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
The National Cancer Institute (NCI) is publishing this Funding Opportunity Announcement (FOA) to request applications for the Program on the Origins of Gastroesophageal Cancers (R01). This new program will build on recent molecular classifications of gastroesophageal cancers, significant understanding of their cancer genomics, and advances in stem cell research to examine and define how these related cancers initially evolve at the cellular level. The program will address the complex mechanisms and effectors that direct the proliferation and expansion of tumor-initiating cells and their progeny to initiate these cancers. The focus of the FOA is on gastric and gastroesophageal junction adenocarcinomas. The program is envisioned to provide unprecedented opportunities to outline the earliest cellular changes in transformation that precede any histological manifestations or neoplasia. This new program will be composed of up to six large R01 research grants (to be supported by this FOA) and one Coordinating Center grant (to be supported by the companion FOA, RFA-CA-21-027).
Funded under RFA-CA-21-026 so far
NIH funded 6 projects under RFA-CA-21-026 in fiscal 2022 to 2026, at 3 institutions. The median yearly award was $912,376.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| Initiation of Diffuse and Intestinal Non-Cardia Gastric Cancer | Columbia University Health Sciences | 2026 | $927,993 |
| The Role of Secondary Bile Acids in Gastro-Esophageal Neoplasia | Columbia University Health Sciences | 2026 | $245,000 |
| Common Stem Cell of Origin for Junctional and Gastric Adenocarcinoma | Wake Forest University Health Sciences | 2026 | $935,434 |
| Gastroesophageal junction stem cells as the origin of Barretts esophagus and cancer | Columbia University Health Sciences | 2025 | $1.9 million |
| Mechanisms underlying gastric intestinal metaplasia and carcinogenesis | Columbia University Health Sciences | 2025 | $1.8 million |
| Cell plasticity in the origin of gastric carcinogenesis | Vanderbilt University Medical Center | 2025 | $2.1 million |
Who has won Cancer Biology Research grants before
From fiscal 2021 to 2025, Cancer Biology Research (93.396) awarded $4.3 billion across 3,142 grant awards, an average of $1.4 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Trustees of Columbia University in the City of New York | New York | 70 | $151 million |
| The Univeristy of Texas M.D. Anderson Cancer Center | Texas | 109 | $144 million |
| Sloan-Kettering Institute for Cancer Research | New York | 66 | $136 million |
| Dana-Farber Cancer Institute, Inc. | Massachusetts | 47 | $107 million |
| The Regents of the University of California, San Francisco | California | 64 | $95.5 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-CA-21-026 still open?
No. It closed on October 8, 2021.
Who can apply for Program on the Origins of Gastroesophageal Cancers (R01 Clinical Trial Optional)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Program on the Origins of Gastroesophageal Cancers (R01 Clinical Trial Optional)?
Closed October 8, 2021. Applications are no longer accepted; the program's newer notices are on this page when there are any.
Who has been funded under RFA-CA-21-026?
NIH RePORTER lists 6 projects funded under RFA-CA-21-026 in fiscal 2022 to 2026, at 3 institutions. The most were at Columbia University Health Sciences, Wake Forest University Health Sciences, Vanderbilt University Medical Center.
Who has won Cancer Biology Research grants before?
The largest recipients over five fiscal years were The Trustees of Columbia University in the City of New York, The Univeristy of Texas M.D. Anderson Cancer Center, Sloan-Kettering Institute for Cancer Research. The program made 3,142 awards worth $4.3 billion in that time.
Similar open grants
- NCCIH Natural Product Mid Phase Clinical Trial (R01 Clinical Trial Required)
- NCCIH Multi-Site Feasibility Clinical Trials of Mind and Body Interventions (R01 Clinical Trial Required)
- Investigator Initiated Clinical Trials of Complementary and Integrative Interventions Delivered Remotely or via mHealth (R01 Clinical Trial Required)
- Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional)
- Competing Revisions to Existing NIH Single Project Research Grants and Cooperative Agreements (Clinical Trial Optional)
- Interventions to expand cancer screening and preventive services to ADVANCE health in populations that experience health disparities (R01, Clinical Trial Required)